Date:_ June 12, 2021	
Your Name:_Qingjie Min	
Manuscript Title: Genomic and ep	igenomic evolution of acquired resistance to chemotherapy combined with
verapamil in esophageal squamous	cell carcinoma
Manuscript number (if known): 15	50203-INS-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China Science Foundation of Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public welfare development and	
	medical writing, article processing charges, etc.)	Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public	

		NATIONAL INSTITUTE OF HEALTH DATA SCIENCE OF PEKING UNIVERSITY	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	

13	Other financial or non- financial interests	None	

Date:_ June 12, 2021	
Your Name:_Yan Wang	
Manuscript Title:_ Genomic and	epigenomic evolution of acquired resistance to chemotherapy combined with
verapamil in esophageal squamo	us cell carcinoma
Manuscript number (if known):	150203-INS-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China Science Foundation of Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public welfare development and	
	medical writing, article processing charges, etc.)	Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public	

		NATIONAL INSTITUTE OF HEALTH DATA SCIENCE OF PEKING UNIVERSITY	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	

13	Other financial or non- financial interests	None	

Date:_ June 12, 2021	
Your Name:_Qingnan Wu	
Manuscript Title: Genomic and epigenomic	evolution of acquired resistance to chemotherapy combined with
verapamil in esophageal squamous cell carc	inoma
Manuscript number (if known): 150203-INS	S-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
ma pro me pro	I support for the present anuscript (e.g., funding, covision of study materials, edical writing, article cocessing charges, etc.) to time limit for this item.	National Natural Science Foundation of China Science Foundation of Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public welfare development and reform pilot projects of Beijing Municipal Medical	

		NATIONAL INSTITUTE OF HEALTH DATA SCIENCE OF PEKING UNIVERSITY	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	

13	Other financial or non- financial interests	None	

Date:_ June 12, 2021	
Your Name:_Xianfeng Li	
Manuscript Title: Genomic and epigenomic evolution of acquired re	sistance to chemotherapy combined with
verapamil in esophageal squamous cell carcinoma	
Manuscript number (if known): 150203-INS-CMED-1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
ma pro me pro	I support for the present anuscript (e.g., funding, covision of study materials, edical writing, article cocessing charges, etc.) to time limit for this item.	National Natural Science Foundation of China Science Foundation of Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public welfare development and reform pilot projects of Beijing Municipal Medical	

		NATIONAL INSTITUTE OF HEALTH DATA SCIENCE OF PEKING UNIVERSITY	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	

Other financial or non- financial interests	None	

ate:_ June 12, 2021
our Name:_Huajing Teng
lanuscript Title:_ Genomic and epigenomic evolution of acquired resistance to chemotherapy combined wit
erapamil in esophageal squamous cell carcinoma
lanuscript number (if known): 150203-INS-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China Science Foundation of Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public welfare development and	
	medical writing, article processing charges, etc.)	Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public	

		NATIONAL INSTITUTE OF HEALTH DATA SCIENCE OF PEKING UNIVERSITY	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	

Other financial or non- financial interests	None	

Date:_ June 12, 2021	
Your Name:_Jiawen Fan	
Manuscript Title: Genomic and epige	nomic evolution of acquired resistance to chemotherapy combined with
verapamil in esophageal squamous ce	II carcinoma
Manuscript number (if known): 1502	03-INS-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China Science Foundation of Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public welfare development and	
	medical writing, article processing charges, etc.)	Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public	

		NATIONAL INSTITUTE OF HEALTH DATA SCIENCE OF PEKING UNIVERSITY	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	

Other financial or non- financial interests	None	

Date:_ June 12, 2021	
Your Name:_Yiren Cao	
Manuscript Title: Genomic and epig	genomic evolution of acquired resistance to chemotherapy combined with
verapamil in esophageal squamous of	cell carcinoma
Manuscript number (if known): 150)203-INS-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China Science Foundation of Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public welfare development and reform pilot projects of	

		NATIONAL INSTITUTE OF HEALTH DATA SCIENCE OF PEKING UNIVERSITY	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	

Other financial or non- financial interests	None	

Date:_ June 12, 2021
Your Name:_ Pingsheng Fan
Manuscript Title: Genomic and epigenomic evolution of acquired resistance to chemotherapy combined with
verapamil in esophageal squamous cell carcinoma
Manuscript number (if known): 150203-INS-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China Science Foundation of Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public welfare development and	
	medical writing, article processing charges, etc.)	Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public	

		NATIONAL INSTITUTE OF HEALTH DATA SCIENCE OF PEKING UNIVERSITY	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	

Other financial or non- financial interests	None	

Date:_ June 12, 2021
Your Name:_Qimin Zhan
Manuscript Title: Genomic and epigenomic evolution of acquired resistance to chemotherapy combined witl
verapamil in esophageal squamous cell carcinoma
Manuscript number (if known): 150203-INS-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China Science Foundation of Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public welfare development and	
	medical writing, article processing charges, etc.)	Peking University Cancer Hospital CAMS Innovation Fund for Medical Sciences Major Program of Shenzhen Bay Laboratory Guangdong Basic and Applied Basic Research Foundation The third round of public	

		NATIONAL INSTITUTE OF HEALTH DATA SCIENCE OF PEKING UNIVERSITY	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	

Other financial or non- financial interests	None	